TGM2 and breast carcinoma: Our findings are supported by the report of Girgoriev et al., [32], which showed stromal TG2 expression in 50% of the human breast carcinomas, while 15% cases stained positive for cytoplasmic TG2; however the correlation of TG2 with disease outcome was not assessed in this study.